Premium
Improved patient acceptability with a transdermal drug‐in‐adhesive oestradiol patch
Author(s) -
Lake Yvonne,
Pinnock Sylvia
Publication year - 2000
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.2000.tb03341.x
Subject(s) - transdermal , medicine , transdermal patch , hormone replacement therapy (female to male) , drug , postmenopausal women , open label , clinical trial , hormone therapy , pharmacology , cancer , breast cancer , testosterone (patch)
SUMMARY The aim of this trial was to assess the relative patient acceptability of two transdermal oestradiol patches used in treatment of oestrogen deficiency in postmenopausal women. Thirty‐five hysterectomised postmenopausal women with no previous experience of transdermal oestradiol delivery systems received treatment with either once‐weekly drug‐in‐adhesive (DIA) patches or twice‐weekly reservoir patches for 4 weeks, and were then switched to the alternative treatment for a further 4 weeks. At the end of the study, the patients completed a questionnaire to assess their relative preference for a number of characteristics of the 2 transdermal systems and, where possible, their preference for transdermal compared with oral hormone replacement therapy. Thirty‐one patients completed the study; four withdrew during treatment with the reservoir patch. The DIA patch was preferred for being ‘easiest to remember to apply’ by 80% of patients (p < 0.01), ‘easiest to open’ and ‘easiest to apply’ by 68% (p = 0.025), and as having ‘best cosmetic appearance’ by 65% (p = 0.05) and ‘best overall skin adhesion’ by 61% (p < 0.01). While 10% of patients rated the reservoir patch as ‘least irritating to the skin’ (p = 0.03), only one patient found this patch ‘most comfortable to wear’ (p < 0.01). The DIA patch was selected by 87% of patients as their preferred treatment overall (p = 0.001). Ninety‐one per cent of 22 responding patients were at least as confident of treatment with transdermal patches as with oral hormone replacement therapy (p = 0.006) and 74% of 27 responders preferred transdermal to oral treatment (p = 0.004). The DIA patch appears to be more acceptable to patients than the reservoir patch as a transdermal oestradiol delivery system for the treatment of postmenopausal oestrogen deficiency. Characteristics of the DIA patch which may account for improved patient acceptance include ease of remembering once‐weekly patch application, improved cosmetic appearance and comfort, and better adhesion.